Special Populations RWE Methods

Special populations RWE methods

are not a single estimator but a coordinated set of design adaptations applied when the population of interest cannot be studied with the default active-comparator, new-user template because the trial that would answer the question is infeasible, too slow, or ethically gated.

The defining move is the same in every case: a trial-derived design element that you would normally take for granted — a single time zero per person, one analytic unit, a stable comparator, a fixed exposure window — has to be re-specified for the biology and the data of the special population before any propensity score or outcome model is fit. Pregnancy forces a gestational-age-anchored exposure window and (for fetal/neonatal outcomes) a two-generation analytic unit. Pediatrics forces age- and weight-normalized dosing and growth-trajectory endpoints rather than fixed-dose, fixed-threshold ones.

Rare and biomarker-defined diseases force external or historical controls (with or without Bayesian borrowing) because a concurrent randomized comparator does not exist at adequate sample size. This entry is the routing layer over those child methods; the worked example below is a pregnancy exposure-window cohort, the cleanest case in which the standard template breaks.

Core conceptual distinction

the estimand and the unit of analysis must be settled before the design. Three choices do the work and they are separable.

1. Whose outcome? In pregnancy, a maternal outcome (e.g., gestational hypertension) keeps the pregnant person as the unit; a fetal/neonatal outcome (e.g., major congenital malformation) makes the pregnancy–infant dyad the unit and requires mother–infant linkage.
2. What is time zero, and is it a calendar date or a developmental landmark? For teratogenicity the biologically meaningful window is organogenesis (roughly the first trimester, gestational weeks ~4–10), not the date of the first prescription fill; anchoring follow-up at the fill date rather than the relevant gestational window is the special-population analogue of immortal-time and exposure-window misclassification.
3. Against what? When a concurrent comparator is impossible (ultra-rare disease, single-arm gene therapy), the comparator becomes an external/historical control and the estimand shifts from a within-cohort contrast to a borrowed-information contrast whose validity rests on exchangeability and outcome-ascertainment comparability rather than on randomization.

The family does not estimate a general-population average effect transported to the subgroup; that transportation is precisely the assumption these designs exist to avoid making blindly.

Pros, cons, and trade-offs

• vs. attempting a randomized trial in the special population: RWE is often the only feasible source — pregnant people are excluded from most pre-approval trials, rare-disease trials cannot accrue, and randomizing children to a dose is frequently unethical. Cost: no randomization, so every confounding and ascertainment threat must be handled by design and analysis, and regulators apply heightened scrutiny to fit-for-purpose data and bias control. Prefer RWE when the trial is infeasible or unethical and a fit-for-purpose data source with adequate outcome capture exists.
• vs. extrapolating a general-population RWE estimate to the subgroup: the special-population design measures the effect in the population of interest, avoiding the transportability leap (different effect modifiers, different competing risks, different baseline risk). Cost: smaller samples, sparser events, and population-specific data gaps. Prefer the dedicated design whenever effect modification or baseline-risk shift between the general and special population is plausible — which is the default assumption in pregnancy, neonates, and rare disease.

When NOT to use — and when it is actively misleading or dangerous

• The data source cannot observe the population-defining structure. A claims database with no gestational dating and no live-birth linkage cannot support a teratogenicity study; forcing it produces fill-date-anchored windows that misclassify organogenesis exposure and silently exclude pregnancies ending in loss (a differential, exposure-related selection that biases toward the null for malformation and can fabricate apparent safety).
• The mother–infant link is incomplete or non-random. If only a subset of dyads links (e.g., infant on a separate plan, delivered out of network), and linkability correlates with exposure or outcome, the dyad cohort is a biased selection — diagnose with link rates by exposure arm before trusting any neonatal estimate.
• The external control is not exchangeable. Borrowing historical or registry controls when standard of care, diagnostic intensity, or outcome definitions have drifted over calendar time injects bias that point estimates hide; dynamic Bayesian borrowing that down-weights on conflict mitigates but does not cure non-exchangeability.
• The genuine question is the general-population effect. If the policy question is population-average, a special- population subgroup design answers a narrower question and should not be generalized back up.
• Sparse events with a default large-sample model. Rare outcomes in small special populations break Wald-based inference; naive logistic/Cox can be separated or badly biased (use exact or Firth-penalized methods instead).

Data-source operational depth

• Claims (FFS vs MA vs commercial): Pregnancy episodes are reconstructed from delivery/outcome codes (live birth, stillbirth, spontaneous/elective abortion) and gestational-age algorithms (e.g., the Margulis/MAX algorithm using diagnosis-based timing), then back-dated to estimate last menstrual period and trimester windows. Failure modes: Medicare Advantage and capitated commercial plans drop fee-for-service encounter claims, so a pregnancy or an infant can vanish from the data — restrict to enrollees with complete FFS-observable medical + pharmacy person-time spanning preconception through delivery, and treat MA-only spans as unobservable, not as "no event." Spontaneous losses and elective terminations are under-captured relative to live births, creating exposure-related left-truncation. Mother– infant linkage requires a deterministic family/subscriber key plus a delivery-to-birth date match within a plausible window; link rates differ by plan type and must be reported.
• EHR: Strong for gestational dating (LMP, ultrasound-derived EDD, problem lists) and for birth/neonatal outcomes when delivery happens in-system, but visit-driven capture means out-of-system deliveries, NICU transfers, and infant primary care elsewhere are differentially lost. Medication orders are not dispensings; confirm actual exposure during the relevant gestational window with linked pharmacy fills where possible.
• Registry (pregnancy, rare-disease, product): The reference standard for adjudicated outcomes (malformation panels, genetically confirmed rare disease, biomarker status) and for enrolling external/historical controls, but enrollment is selective (consent, referral bias) and exposure capture is often patient-reported. Transportability from the registry population to the treated cohort is the binding assumption for external controls.
• Linked claims–EHR–vital/birth records: The ideal substrate — EHR gestational dating + claims completeness + vital- records birth and fetal-death certificates that recover the losses claims miss — but linkage selects the linkable subset and introduces date discrepancies (LMP vs delivery vs claim service date) that must be reconciled before windows are set.

Worked example (pregnancy exposure-window cohort, claims)

Question: risk of major congenital malformation after first-trimester exposure to drug X vs an active comparator Y used for the same maternal indication, in a commercial + Medicaid claims database with mother–infant linkage.

1. Pregnancy episode: identify live-birth deliveries from delivery codes; estimate the last-menstrual-period (LMP) date by subtracting an algorithm-derived gestational age from the delivery date, defining the pregnancy span [LMP, delivery].
2. Enrollment: require continuous FFS-observable medical + pharmacy enrollment from 90 days before LMP through 90 days after delivery, excluding any MA-only person-time so that absence of a fill is a true non-exposure, not missingness.
3. Exposure window: classify the dyad as exposed if a fill of drug X with `days_supply` overlapping gestational weeks 4–10 (organogenesis) covers any day in that window; assign the comparator arm analogously — note this is fill-overlap of the gestational window, not the fill date.
4. Unit and linkage: link each delivery to its infant via the family/subscriber key and a birth date within ±30 days of the delivery claim; the analytic unit is the dyad, and the malformation outcome is read from the infant's first-year claims using a validated algorithm.
5. Time zero / baseline: covariates (maternal age, comorbidities, prior pregnancy loss, healthcare utilization, folic-acid/teratogen co-exposures) measured in [LMP − 90d, LMP] to avoid conditioning on post-conception mediators.
6. Analysis: propensity-score overlap weighting on the baseline covariates; because malformations are rare, fit a Firth-penalized logistic model and report the absolute risk difference per 1,000 live births with a sensitivity analysis on gestational-dating error, link-window width, and inclusion of pregnancies ending in loss.

Decision diagram

flowchart TD
  Q[Special population?] -->|Pregnant / postpartum| Preg[Reconstruct pregnancy episode<br/>+ back-date LMP]
  Q -->|Pediatric / neonatal| Ped[Age/weight dose normalization<br/>+ growth-trajectory endpoints]
  Q -->|Rare or biomarker-defined| Rare[External / historical control<br/>+ optional Bayesian borrowing]
  Preg -->|Maternal outcome| Mat[Unit = pregnant person]
  Preg -->|Fetal / neonatal outcome| Dyad[Unit = mother-infant dyad<br/>requires linkage]
  Mat --> Win[Gestational-age exposure window<br/>e.g. organogenesis wk 4-10]
  Dyad --> Win
  Win --> Sparse{Events sparse?}
  Rare --> Sparse
  Ped --> Sparse
  Sparse -->|Yes| Exact[Firth-penalized / exact inference]
  Sparse -->|No| Std[Standard PS-weighted model]
  Exact --> Out[Report with attrition, link rates,<br/>and sensitivity analyses]
  Std --> Out

gantt
  title Pregnancy exposure-window dyad timeline (claims)
  dateFormat YYYY-MM-DD
  axisFormat %b %Y
  section Mother
  Pre-LMP covariate + observable window :done, pre, 2023-07-03, 90d
  Organogenesis exposure window (wk 4-10) :crit, org, 2023-10-22, 42d
  Pregnancy span (LMP to delivery) :active, preg, 2023-10-01, 280d
  Delivery :milestone, del, 2024-07-07, 0d
  section Infant
  Linked infant first-year outcome ascertainment :infant, 2024-07-07, 365d

Worked example

Scenario

Five patients represent five special populations commonly studied in RWE. For each, a researcher wants to estimate how a drug affects a clinically meaningful outcome. The table below shows why the default study design would fail for that population, what the specific challenge is in the data, and what methodological adjustment is required. No single patient here uses the standard adult-cohort template without modification.

Dataset

One representative patient per special population with the design challenge each raises.

Steps

Result

Each special population requires a tailored adjustment before a single line of analysis code is written. Pregnant patients need a gestational-age anchor and a linked infant record. Pediatric patients need weight-adjusted dose and growth endpoints. Elderly patients with high competing risks need a competing-risks model rather than standard survival analysis. Rare-disease patients need an external control with explicit exchangeability checks. Biomarker-defined patients need confirmed molecular eligibility from a linked pathology or registry source. Applying the default adult cohort template to any of these five populations produces a different type of error — window misclassification, dose mislabeling, inflated survival estimates, non-exchangeable historical comparison, or diluted biomarker-eligibility — which is why the field treats these as a named family of methods rather than minor footnotes.

Trade-offs

Runnable example

import pandas as pd
import numpy as np

PRE_LMP_DAYS = 90          # FFS-observable lookback before conception for covariates + non-exposure
POST_DEL_DAYS = 90         # observable follow-through after delivery
ORGANOGENESIS = (4, 10)    # gestational weeks defining the teratogenic exposure window
LINK_WINDOW_DAYS = 30      # delivery-to-infant-birth match tolerance

def build_pregnancy_dyad_cohort(deliveries, rx, enroll, links):
    d = deliveries[deliveries["outcome"] == "LIVEBIRTH"].copy()
    # Back-date last menstrual period from delivery date and algorithm gestational age.
    d["lmp"] = d["delivery_date"] - pd.to_timedelta(d["ga_weeks"] * 7, unit="D")
    d["org_start"] = d["lmp"] + pd.to_timedelta(ORGANOGENESIS[0] * 7, unit="D")
    d["org_end"]   = d["lmp"] + pd.to_timedelta(ORGANOGENESIS[1] * 7, unit="D")

    # Continuous FFS-observable enrollment across [lmp - 90d, delivery + 90d]; exclude MA-only spans.
    e = enroll[~enroll["ma_only"]].merge(
        d[["person_id", "lmp", "delivery_date"]], on="person_id")
    e["covers"] = ((e["enroll_start"] <= e["lmp"] - pd.Timedelta(days=PRE_LMP_DAYS)) &
                   (e["enroll_end"]   >= e["delivery_date"] + pd.Timedelta(days=POST_DEL_DAYS)))
    eligible = set(e.loc[e["covers"], "person_id"])
    d = d[d["person_id"].isin(eligible)].copy()

    # Exposure = a study/comparator fill whose supplied days overlap the organogenesis window.
    r = rx.merge(d[["person_id", "org_start", "org_end"]], on="person_id")
    r["supply_end"] = r["fill_date"] + pd.to_timedelta(r["days_supply"], unit="D")
    r["overlaps"] = (r["fill_date"] <= r["org_end"]) & (r["supply_end"] >= r["org_start"])
    exp = (r[r["overlaps"]]
             .sort_values(["person_id", "fill_date"])
             .groupby("person_id")
             .agg(arm=("drug_class", "first")).reset_index())
    cohort = d.merge(exp, on="person_id", how="inner")   # keep dyads exposed to either arm in-window

    # Link each delivery to its infant (analytic unit = dyad) within the date tolerance.
    cohort = cohort.merge(links, on="person_id", how="inner")
    ok = (cohort["infant_birth_date"] - cohort["delivery_date"]).abs() <= pd.Timedelta(days=LINK_WINDOW_DAYS)
    cohort = cohort[ok].copy()

    cohort["baseline_start"] = cohort["lmp"] - pd.Timedelta(days=PRE_LMP_DAYS)
    return cohort[["person_id", "infant_id", "arm", "lmp",
                   "org_start", "org_end", "delivery_date", "baseline_start"]]

library(data.table)
PRE_LMP_DAYS   <- 90L
POST_DEL_DAYS  <- 90L
ORG_START_WK   <- 4L
ORG_END_WK     <- 10L
LINK_WINDOW    <- 30L

build_pregnancy_dyad_cohort <- function(deliveries, rx, enroll, links) {
  setDT(deliveries); setDT(rx); setDT(enroll); setDT(links)

  d <- deliveries[outcome == "LIVEBIRTH"]
  d[, lmp := delivery_date - ga_weeks * 7L]                 # back-date conception
  d[, `:=`(org_start = lmp + ORG_START_WK * 7L,
           org_end   = lmp + ORG_END_WK   * 7L)]

  # FFS-observable continuous enrollment across [lmp - 90, delivery + 90]; drop MA-only spans.
  e <- merge(enroll[ma_only == FALSE], d[, .(person_id, lmp, delivery_date)], by = "person_id")
  ok_enr <- e[enroll_start <= lmp - PRE_LMP_DAYS &
              enroll_end   >= delivery_date + POST_DEL_DAYS, unique(person_id)]
  d <- d[person_id %chin% ok_enr]

  # Exposure: study/comparator fill whose supplied days overlap the organogenesis window.
  r <- merge(rx, d[, .(person_id, org_start, org_end)], by = "person_id")
  r[, supply_end := fill_date + days_supply]
  r <- r[fill_date <= org_end & supply_end >= org_start]
  setorder(r, person_id, fill_date)
  exp <- r[, .(arm = drug_class[1L]), by = person_id]
  cohort <- merge(d, exp, by = "person_id")

  # Dyad linkage within the delivery-to-birth date tolerance.
  cohort <- merge(cohort, links, by = "person_id")
  cohort <- cohort[abs(as.integer(infant_birth_date - delivery_date)) <= LINK_WINDOW]

  cohort[, baseline_start := lmp - PRE_LMP_DAYS]
  cohort[, .(person_id, infant_id, arm, lmp, org_start, org_end, delivery_date, baseline_start)]
}

%let pre_lmp   = 90;   /* observable lookback before LMP */
%let post_del  = 90;   /* observable follow-through after delivery */
%let org_start = 28;   /* organogenesis start: 4 weeks * 7 days */
%let org_end   = 70;   /* organogenesis end:  10 weeks * 7 days */
%let link_win  = 30;   /* delivery-to-birth date tolerance */

/* Live-birth episodes with back-dated LMP and organogenesis window. */
proc sql;
  create table episode as
  select person_id,
         delivery_date,
         delivery_date - ga_weeks*7              as lmp       format=date9.,
         delivery_date - ga_weeks*7 + &org_start as org_start format=date9.,
         delivery_date - ga_weeks*7 + &org_end   as org_end   format=date9.
  from work.deliveries
  where outcome = 'LIVEBIRTH';
quit;

/* FFS-observable continuous enrollment across [lmp-90, delivery+90]; exclude MA-only person-time. */
proc sql;
  create table enrolled as
  select e2.*
  from episode e2
  where exists (
    select 1 from work.enroll en
    where en.person_id = e2.person_id
      and en.ma_only = 0
      and en.enroll_start <= e2.lmp - &pre_lmp
      and en.enroll_end   >= e2.delivery_date + &post_del
  );
quit;

/* Arm = drug_class of the earliest study/comparator fill overlapping the organogenesis window. */
/* Join qualifying fills to the enrolled episode, sort by person/fill, then keep the earliest per person. */
proc sql;
  create table cand as
  select en.person_id, en.lmp, en.org_start, en.org_end, en.delivery_date,
         r.fill_date, r.drug_class
  from enrolled en
  inner join work.rx r
    on r.person_id = en.person_id
   and r.drug_class in ('STUDY','COMPARATOR')
   and r.fill_date <= en.org_end
   and r.fill_date + r.days_supply >= en.org_start;
quit;

proc sort data=cand;
  by person_id fill_date;
run;

data exposed;
  set cand;
  by person_id;
  if first.person_id;          /* earliest overlapping fill; arm is non-missing by construction */
  length arm $12;
  arm = drug_class;
  keep person_id lmp org_start org_end delivery_date arm;
run;

/* Link to the infant (analytic unit = dyad) within the date tolerance. */
proc sql;
  create table cohort as
  select x.person_id, l.infant_id, x.arm, x.lmp,
         x.org_start, x.org_end, x.delivery_date,
         x.lmp - &pre_lmp as baseline_start format=date9.
  from exposed x
  inner join work.links l
    on l.person_id = x.person_id
   and abs(l.infant_birth_date - x.delivery_date) <= &link_win;
quit;

Citations

1. [1]Huybrechts KF, Bateman BT, Hernández-Díaz S. Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy. Pharmacoepidemiology and Drug Safety. 2019;28(7):906-922.
2. [2]Suissa S, Dell'Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety. 2020;29(9):1101-1110.

1. [3]Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. Journal of Clinical Epidemiology. 2016;79:70-75.

1. [4]Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clinical Pharmacology & Therapeutics. 2019;106(1):36-39.